Last reviewed · How we verify
rosuvastatin and clopidogrel
At a glance
| Generic name | rosuvastatin and clopidogrel |
|---|---|
| Sponsor | The Third Affiliated Hospital of Guangzhou Medical University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Optimal Antiplatelet and Lipid Therapy in ACS With DES: OPACT Trial (NA)
- A Polypill for Acute Coronary Syndrome (PHASE2)
- A EUROpean Randomized Study on Blood-thinners and Cholesterol-lowering Treatments to Prevent Future Vascular Events in People With Covert Brain Infarcts (CBI) (PHASE3)
- Concomitant Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Moderate and Moderate-to-severe Stroke (PHASE3)
- Combining Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Large-vessel Ischemic Stroke (PHASE3)
- Polypill in Acute Coronary Syndrome (PHASE2)
- Statin and Dual Antiplatelet Therapy to Prevent Early Neurological Deterioration in Branch Atheromatous Disease (PHASE2)
- Effect of Enhanced External Counterpulsation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: